Overview of Telix Pharmaceuticals Limited's General Meeting Address

Telix Pharmaceuticals Limited (ASX: $TLX) provided the Chairman and CEO's Addresses to the General Meeting of Shareholders, discussing the company's growth strategy, acquisitions, and potential Nasdaq listing. The meeting was held at The Wesley Conference Centre, Sydney, and online.

Chairman and CEO's Commentary on Growth Strategy and Acquisitions

Good morning shareholders and colleagues. I'm Kevin McCann, Chairman of Telix Pharmaceuticals Limited, and I will chair the meeting today. Dr Behrenbruch, Telix's Managing Director and Group Chief Executive Officer, will provide further commentary on our mergers and acquisitions (M&A) strategy and recent strategic acquisitions. The meeting aims to refresh the company's 15% 'placement capacity' under ASX Listing Rule 7.1, in light of Telix's growth strategy. Telix has been focusing on M&A and in-licensing of high-potential assets, technologies, and capabilities, aiming to address significant unmet medical needs in oncology and rare diseases. The acquisitions signify a new phase in the transformation and maturation of our Company as a leading global radiopharmaceutical company.

Summary of Telix's General Meeting Address and Outlook

Telix Pharmaceuticals Limited addressed shareholders at the General Meeting, highlighting the company's growth strategy, acquisitions, and potential Nasdaq listing. The Chairman discussed the need to refresh the company's 'placement capacity' to pursue further growth opportunities, including the potential Nasdaq listing. CEO Christian Behrenbruch emphasized the company's transformation and growth, financing product development from earnings, and pursuing a growth strategy through mergers and acquisitions, licensing, and partnerships. Telix's focus on late-stage therapeutics pipeline, second-generation products, precision medicine, and supply chain and manufacturing footprint underpins its strong growth trajectory into the future. The acquisitions of ARTMS, IsoTherapeutics Group, QSAM Biosciences, Lightpoint, and Dedicaid strategically enhance the company's capabilities and commercial portfolio, aiming to deliver new products, technologies, and clinical outcomes.